356 related articles for article (PubMed ID: 33610284)
1. [How to perform leukapheresis for procurement of the staring material used for commercial CAR T-cell manufacturing: A consensus from experts convened by the SFGM-TC].
Carnoy S; Beaumont JL; Kanouni T; Parquet N; Beauvais D; Hequet O; Kanold J; Ballot C; Mialou V; Reppel L; Damaj G; Yakoub-Agha I; Chabannon C
Bull Cancer; 2021 Mar; 108(3):295-303. PubMed ID: 33610284
[TBL] [Abstract][Full Text] [Related]
2. [Eligibility of patients for CAR T-cell: Expert opinion-based collaborative work by the SFGM-TC].
Beauvais D; Bachy E; Baruchel A; Bay JO; Caillot D; Cartron G; Damaj G; Furst S; Le Gouill S; Morschhauser F; Rabian F; Rubio MT; Thieblemont C; Yakoub-Agha I
Bull Cancer; 2021; 108(7-8):725-729. PubMed ID: 33423776
[TBL] [Abstract][Full Text] [Related]
3. [Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Alsuliman T; Drieu La Rochelle L; Campidelli A; Duléry R; Fayard A; Mamez AC; Mear JB; Schneider PO; Trevet A; Vicente C; Yakoub-Agha I
Bull Cancer; 2021 Dec; 108(12S):S65-S71. PubMed ID: 33678408
[TBL] [Abstract][Full Text] [Related]
4. [The CAR-T cells are here].
Croizier C; Douge A; Bay JO; Lemal R
Bull Cancer; 2018 Sep; 105(9):743-745. PubMed ID: 30119830
[TBL] [Abstract][Full Text] [Related]
5. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).
Yakoub-Agha I; Chabannon C; Bader P; Basak GW; Bonig H; Ciceri F; Corbacioglu S; Duarte RF; Einsele H; Hudecek M; Kersten MJ; Köhl U; Kuball J; Mielke S; Mohty M; Murray J; Nagler A; Robinson S; Saccardi R; Sanchez-Guijo F; Snowden JA; Srour M; Styczynski J; Urbano-Ispizua A; Hayden PJ; Kröger N
Haematologica; 2020; 105(2):297-316. PubMed ID: 31753925
[TBL] [Abstract][Full Text] [Related]
6. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
[TBL] [Abstract][Full Text] [Related]
7. CAR T-cells in acute lymphoblastic leukemia: Current results.
Dourthe ME; Baruchel A
Bull Cancer; 2021 Oct; 108(10S):S40-S54. PubMed ID: 34920807
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor T-cell therapy: Foundational science and clinical knowledge for pharmacy practice.
Dushenkov A; Jungsuwadee P
J Oncol Pharm Pract; 2019 Jul; 25(5):1217-1225. PubMed ID: 30890066
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.
Westin JR; Kersten MJ; Salles G; Abramson JS; Schuster SJ; Locke FL; Andreadis C
Am J Hematol; 2021 Oct; 96(10):1295-1312. PubMed ID: 34310745
[TBL] [Abstract][Full Text] [Related]
10. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
11. Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture.
Tyagarajan S; Schmitt D; Acker C; Rutjens E
Cytotherapy; 2019 Dec; 21(12):1198-1205. PubMed ID: 31837735
[TBL] [Abstract][Full Text] [Related]
12. A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?
Zhang J; Li J; Ma Q; Yang H; Signorovitch J; Wu E
Adv Ther; 2020 Jul; 37(7):3040-3058. PubMed ID: 32524498
[TBL] [Abstract][Full Text] [Related]
13. Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing.
Qayed M; McGuirk JP; Myers GD; Parameswaran V; Waller EK; Holman P; Rodrigues M; Clough LF; Willert J
Cytotherapy; 2022 Sep; 24(9):869-878. PubMed ID: 35718701
[TBL] [Abstract][Full Text] [Related]
14. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
Chow VA; Shadman M; Gopal AK
Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
[TBL] [Abstract][Full Text] [Related]
15. Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies.
Al-Juhaishi T; Ahmed S
Curr Hematol Malig Rep; 2021 Feb; 16(1):32-39. PubMed ID: 33630232
[TBL] [Abstract][Full Text] [Related]
16. Leukapheresis for CAR-T cell production and therapy.
Pessach I; Nagler A
Transfus Apher Sci; 2023 Dec; 62(6):103828. PubMed ID: 37838564
[TBL] [Abstract][Full Text] [Related]
17. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
[TBL] [Abstract][Full Text] [Related]
18. [The care process of patient receiving CAR T-cell therapy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Beauvais D; Andrianne C; Aubrun C; Berquier M; Bole S; Caulier A; Courbon C; Delorme J; Fournier I; François G; Jaivenois MF; Le Bars L; Mussot I; Vercasson M; Wallart Brejaud A; Yakoub-Agha I; Lacroix D
Bull Cancer; 2020 Dec; 107(12S):S170-S177. PubMed ID: 32891406
[TBL] [Abstract][Full Text] [Related]
19. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
Sharma P; King GT; Shinde SS; Purev E; Jimeno A
Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
[TBL] [Abstract][Full Text] [Related]
20. [Reporting data of patients receiving CAR T cell therapy into the EBMT registry: Guidelines of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Vasseur A; Karam M; Chaillou D; Colonnese E; Dantin C; Latiere C; Meziane Y; Pereira M; Yakoub-Agha I; Chabannon C; Raus N
Bull Cancer; 2020 Dec; 107(12S):S178-S184. PubMed ID: 31831153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
